Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- AstraZeneca’s COVID Antibody, Daiichi’s TROP2 ADC, and More Up for Review on Dec. 6
November 25, 2024
- Pharma Renews Call for Abolishing Off-Year Revisions, but MHLW Stays Put with Honebuto
November 22, 2024
- Pharma Pushes to Scrap Off-Year Revisions; LDP Members Urge Fresh Talks by 4 Ministers
November 22, 2024
- Health Minister Committed to Drug Supplies, Repeats Plan to Base Off-Year Debate on Honebuto
November 21, 2024
- DPP Requests Promotion Self-Medication Tax Break in 3-Way Talks
November 21, 2024
- 3 Parties Reach Deal on Economic Plan, Off-Year “Abolition” Not Spelled Out
November 21, 2024
- DPP Leader Poised to Urge 4 Ministers to Abolish Off-Year Revisions
November 20, 2024
- MHLW Issues Optimal Use Guideline for Kisunla
November 20, 2024
- Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
- Pediatric Forms of Jakavi, More Drugs to Get Listing; Eylea Biosimilar Not on Roster
November 19, 2024
- DPP Prods Ruling Camp to Be More Specific on Off-Year Revision in Economic Plan
November 19, 2024
- MHLW Eyes Hiking Copay Cap to Curb Healthcare Spending
November 18, 2024
- LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
- MHLW Orders Label Revisions for Epadel, Lotriga, and More
November 15, 2024
- Opposition CDP Eyes Nonpartisan Bill to Scrap Off-Year Drug Price Revisions
November 14, 2024
- MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
- Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
- Japan to Apply Leqembi’s General Pricing Rules for Similar AD Therapies
November 14, 2024
- Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
- Xocova Price to Be Trimmed by 300 Yen after CEA; No Change for Mounjaro
November 14, 2024
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…